KEGG   PATHWAY: map07045Help
Entry
map07045          Drug      Pathway                                
Name
Antineoplastics - protein kinases inhibitors
Class
BRITE hierarchy
Pathway map
Antineoplastics - protein kinases inhibitors
map07045

All organismsOrtholog table
Compound
D01441  
Imatinib mesilate (JAN)
D01977  
Gefitinib (JAN/USAN/INN)
D02714  
Everolimus (JAN/USAN/INN)
D03218  
Axitinib (JAN/USAN)
D03252  
Bosutinib (USAN)
D03257  
Trastuzumab (genetical recombination) (JAN)
D03350  
Canertinib dihydrochloride (USAN)
D03455  
Cetuximab (genetical recombination) (JAN)
D03658  
Dasatinib (INN)
D04014  
Enzastaurin hydrochloride (JAN/USAN)
D04023  
Erlotinib hydrochloride (JAN/USAN)
D04024  
Lapatinib tosilate hydrate (JAN)
D04696  
Lestaurtinib (USAN/INN)
D05029  
Midostaurin (USAN/INN)
D05350  
Panitumumab (genetical recombination) (JAN)
D05380  
Pazopanib hydrochloride (JAN/USAN)
D05446  
Pertuzumab (genetical recombination) (JAN)
D05819  
Semaxanib (USAN/INN)
D06005  
Tandutinib (USAN/INN)
D06068  
Temsirolimus (JAN/USAN/INN)
D06272  
Sorafenib tosilate (JAN)
D06285  
Vatalanib (USAN/INN)
D06402  
Sunitinib malate (JAN/USAN)
D06407  
Vandetanib (JAN/USAN/INN)
D06413  
Nilotinib hydrochloride hydrate (JAN)
D06414  
Dasatinib hydrate (JAN)
D06678  
Motesanib
D07907  
Erlotinib (INN)
D08066  
Imatinib (INN)
D08108  
Lapatinib (INN)
D08524  
Sorafenib (USAN/INN)
D08552  
Sunitinib (INN)
D08947  
Motesanib phosphate (JAN)
D08953  
Nilotinib (USAN/INN)
D09724  
Afatinib (USAN/INN)
D09728  
Bosutinib hydrate (JAN)
D09731  
Crizotinib (JAN/USAN/INN)
D09733  
Afatinib maleate (JAN)
D09955  
Quizartinib (USAN/INN)
D09956  
Quizartinib dihydrochloride (USAN)
D09959  
Ruxolitinib (USAN/INN)
D09960  
Ruxolitinib phosphate (JAN/USAN)
D09980  
Trastuzumab emtansine (genetical recombination) (JAN)
D10202  
Bafetinib (USAN)
Reference
  Authors
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD.
  Title
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
  Journal
Cancer Cell 7:129-41 (2005)
Reference
  Authors
Chow LQ, Eckhardt SG.
  Title
Sunitinib: from rational design to clinical efficacy.
  Journal
J Clin Oncol 25:884-96 (2007)
Reference
  Authors
Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.
  Title
Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib.
  Journal
J Med Chem : (2007)
Reference
  Authors
Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.
  Title
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
  Journal
Gastroenterology 128:270-9 (2005)
Reference
  Authors
von Mehren M.
  Title
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
  Journal
Clin Colorectal Cancer 6 Suppl 1:S30-4 (2006)
Reference
  Authors
Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.
  Title
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
  Journal
Clin Cancer Res 13:4874-81 (2007)
DBGET integrated database retrieval system